Who makes Apixaban vs. DAPT?

Apixaban vs. DAPT is developed by DR. XAVIER FREIXA.

What development phase is Apixaban vs. DAPT in?

Apixaban vs. DAPT is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Apixaban vs. DAPT

DR. XAVIER FREIXA · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Apixaban vs. DAPT
Sponsor	DR. XAVIER FREIXA
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Apixaban vs. DAPT CI brief — competitive landscape report
Apixaban vs. DAPT updates RSS · CI watch RSS
DR. XAVIER FREIXA portfolio CI